Modalis Therapeutics Corporation 4883
ζ ͺεΌδΌšη€Ύγƒ’γƒ€γƒͺγ‚Ή Β· Drug Manufacturers - Specialty & Generic Β· Growth
Governance Compliance: TSE Status: Untracked
Similar β€Ί
Fact Sheet (PDF)
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. The company is developing therapies for genetic diseases using its proprietary CRISPR-GNDM an epigenome editing technology that combines dCas9. It also develops various therapeutics for muscle disorders, cardiomyopathy, and CNS disorders. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was incorporated in 2016 and is headquartered in Chuo, Japan.
Price
Β₯34
Market Cap
Β₯2.9B
Ent. Value
Β₯135M
Net Cash
Β₯2.8B
Shares Out.
86.7M
P / E
β€”
EV / EBIT
β€”
P / Book
1.07Γ—
P / NCAV
1.08Γ—
Div. Yield
β€”
⬇ Excel
Metric FY 2025
EDINET β†—
FY 2024
EDINET β†—
FY 2023
EDINET β†—
FY 2022
EDINET β†—
FY 2021
EDINET β†—
FY 2020
EDINET β†—
Net Sales β€” β€” β€” Β₯40M Β₯1M Β₯342M
SG&A Β₯232M Β₯245M Β₯268M Β₯242M Β₯231M Β₯208M
Operating Income Β₯-2.2B Β₯-1.3B Β₯-2.4B Β₯-2.1B Β₯-1.2B Β₯-398M
Non-Operating Income Β₯82M Β₯65M Β₯40M Β₯77M Β₯13M Β₯0M
Interest Income Β₯4M Β₯0M Β₯0M Β₯0M Β₯0M Β₯0M
Non-Operating Expenses Β₯19M Β₯30M Β₯21M Β₯10M Β₯5M Β₯42M
Interest Expense Β₯3M Β₯4M Β₯4M Β₯5M Β₯1M β€”
Ordinary Income Β₯-2.1B Β₯-1.3B Β₯-2.4B Β₯-2.0B Β₯-1.2B Β₯-440M
Pre-tax Income Β₯-2.2B Β₯-1.3B Β₯-2.4B Β₯-2.7B Β₯-745M Β₯-440M
Income Taxes Β₯2M Β₯1M Β₯1M Β₯-4M Β₯-6M Β₯9M
Current Tax Β₯2M Β₯1M Β₯1M Β₯1M Β₯1M Β₯1M
Deferred Tax β€” β€” β€” Β₯-6M Β₯-8M Β₯8M
Net Income (owners) Β₯-2.2B Β₯-1.3B Β₯-2.4B Β₯-2.7B Β₯-739M Β₯-448M
Comprehensive Income Β₯-2.1B Β₯-1.3B Β₯-2.4B Β₯-2.7B Β₯-732M Β₯-450M
EBITDA β€” β€” Β₯-2.4B Β₯-1.9B Β₯-1.2B Β₯-341M
EPS Β₯-27.86 Β₯-28.57 Β₯-77.24 Β₯-92.85 Β₯-25.70 Β₯-17.02
Shares Outstanding 86.7M 69.4M 33.4M 29.4M 29.0M 28.5M
Shares Issued (total) 86.7M 69.4M 33.4M 29.4M 29.0M 28.5M